Evotec up 7% in early trade after 9-month revenue, earnings beat

By Reuters News

** Evotec's EVTG.DE shares are up around 7% in early Frankfurt trade after the German drug discovery company's preliminary nine-month results topped expectations

** The company said on Tuesday it expected 9-month group revenues of about €465.0 million, with adjusted group EBITDA of about -€42.8 million

** That compares with consensus view of €429 million for revenue and adjusted EBITDA of -€45 million, a local trader says

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk